Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
GXAI
Gaxos.ai
Sponsored
content by Gaxos.ai
JO
Jolt_Communications
Community Contributor
Gaxos.ai: Early-Stage AI Innovator in Gaming & Health
Key Takeaways Dual AI focus – Gaxos.ai builds AI-powered tools for game developers (via Unity integrations) and AI-driven health services under its RNK Health brand. First signs of commercial traction – After years of development, the company reported ~$24k in H1 2025 revenue, mainly from wellness pilot programs.
View narrative
US$2.21
FV
50.2% undervalued
intrinsic discount
119.00%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
New
narrative
Microsoft
PI
PicaCoder
Community Contributor
After the AI Party: A Sobering Look at Microsoft's Future
The world has been captivated by the artificial intelligence boom, and no company has ridden the wave of investor enthusiasm quite like Microsoft. Buoyed by its strategic partnership with OpenAI and the integration of AI across its product ecosystem, the company's valuation has soared to unprecedented heights.
View narrative
US$500.00
FV
3.4% overvalued
intrinsic discount
6.75%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
1
users have commented on this narrative
15
users have followed this narrative
8 days ago
author updated this narrative
Amazon.com
ZW
Zwfis
Community Contributor
Amazon's Future Rises as Stock Price Falls: A Long-Term Investment Vision
Amazon is a stock I am very interested in right now especially with the recent price drops that it has been experiencing since its 2Q25 results. A summary of Amazon as stated by Fiscal.ai: "Amazon.com, Inc.
View narrative
US$234.75
FV
1.4% undervalued
intrinsic discount
13.60%
Revenue growth p.a.
Set Fair Value
8
users have liked this narrative
1
users have commented on this narrative
8
users have followed this narrative
New
narrative
Verve Group
TI
TibiT
Community Contributor
Verve Group: A Tale of Three Futures
Verve Group stands at a critical juncture. After a history of explosive growth, the company has been hit by significant operational headwinds, primarily the difficult and costly migration to a unified technology platform and unfavorable currency exchange rates.
View narrative
€4.02
FV
47.4% undervalued
intrinsic discount
8.50%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
Updated
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Village Farms International
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
Regulatory Hurdles In Germany Will Pressure Margins Though Gains Beckon
Key Takeaways Broad international expansion and regulatory shifts are driving growth but expose the company to pricing pressure, margin volatility, and operational complexity risks. Investments in cannabis cultivation and efficiency gains may be negated by stricter environmental regulations, rising compliance costs, and competitive threats from alternative production methods.
View narrative
US$3.25
FV
10.8% undervalued
intrinsic discount
-4.59%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Karyopharm Therapeutics
AN
AnalystLowTarget
Consensus Narrative from 6 Analysts
Liquidity Strains And Overreliance Will Mar Outlook But Support Recovery
Key Takeaways Heavy reliance on a single drug and looming debt maturity create significant operational and financial vulnerability amid intensifying industry competition. Regulatory constraints, limited resources, and weak partnerships threaten pricing power, expansion efforts, and long-term growth prospects.
View narrative
US$8.00
FV
30.1% undervalued
intrinsic discount
17.06%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
OptimizeRx
AN
AnalystLowTarget
Consensus Narrative from 6 Analysts
Heightened Data Privacy And Provider Skepticism Will Hinder Healthcare Transformation
Key Takeaways Heightened regulatory scrutiny and data privacy restrictions threaten platform effectiveness, increase compliance costs, and limit future growth prospects. Declining provider engagement and digital tool commoditization risk compressing margins, while concentrated revenue sources heighten vulnerability to client loss.
View narrative
US$11.00
FV
54.4% overvalued
intrinsic discount
7.02%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
GrowGeneration
AN
AnalystLowTarget
Consensus Narrative from 2 Analysts
US Cannabis Regulations And Retail Shifts Will Limit Prospects
Key Takeaways Regulatory uncertainty and stricter environmental policies threaten to reduce demand for GrowGeneration's core products, heightening revenue and earnings risks. Shifts toward e-commerce, commoditization, and industry consolidation put pressure on margins and erode the company's competitive advantage in retail specialty supplies.
View narrative
US$1.50
FV
4.7% overvalued
intrinsic discount
-6.02%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Creo Medical Group
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
Hospital Budget Pressures And Slow Adoption Will Limit Gains Slightly
Key Takeaways Adoption of Creo's technology faces hurdles from slow hospital procurement, budget pressures, and delayed integration of clinical evidence, restricting near-term revenue growth. Expansion is challenged by geopolitical risks, competitive medtech landscape, and potential margin pressures from ongoing high R&D spend and formidable incumbents.
View narrative
UK£0.40
FV
65.6% undervalued
intrinsic discount
64.63%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Treace Medical Concepts
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
Minimally Invasive Bunion Solutions Will Broaden Market Penetration
Key Takeaways Broadening of product portfolio and positive clinical adoption positions Treace for increased market penetration and long-term revenue growth. Improved cost discipline and expanding salesforce support enhanced margins and international market opportunities.
View narrative
US$8.35
FV
15.7% undervalued
intrinsic discount
9.54%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
5 days ago
author updated this narrative
DNA
Ginkgo Bioworks Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Life Sciences Automation Will Stagnate Amid Regulatory Challenges
Key Takeaways Overly optimistic revenue and margin expectations face obstacles from slow sector adoption, underused lab capacity, and challenges in monetizing new AI and data offerings. Regulatory, geopolitical, and competitive pressures may limit long-term growth, especially as customer acquisition and core-product commoditization risks increase.
View narrative
US$10.33
FV
33.5% overvalued
intrinsic discount
-9.05%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
49
users have followed this narrative
5 days ago
author updated this narrative
Navitas Semiconductor
AN
AnalystConsensusTarget
Consensus Narrative from 8 Analysts
GaN EV And Data Center Wins Will Unlock New Opportunities
Key Takeaways Projected growth in data centers and automotive sectors, supported by strategic partnerships and a robust backlog of design wins, boosts future revenue outlook. Cost-reduction initiatives aim to improve net margins and support positive EBITDA, enhancing financial positioning for 2026.
View narrative
US$6.74
FV
0.5% overvalued
intrinsic discount
31.07%
Revenue growth p.a.
Set Fair Value
4
users have liked this narrative
1
users have commented on this narrative
69
users have followed this narrative
5 days ago
author updated this narrative
Dye & Durham
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
Upgraded Workflow Software And Debt Reduction Will Secure Future Success
Key Takeaways Emphasis on organic growth and enhanced software could boost revenue via higher adoption and customer satisfaction. Debt reduction and strategic divestments may strengthen cash flow and financial health.
View narrative
CA$15.75
FV
32.9% undervalued
intrinsic discount
2.63%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
5 days ago
author updated this narrative
Value any company in seconds
Popular companies